Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
- PMID:26897480
- DOI: 10.1016/j.jamcollsurg.2015.12.017
Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) has demonstrated proven benefit in tumor regression and improved long-term local control for patients with locally advanced rectal cancer. However, precise analysis of the optimal waiting time that maximizes oncologic benefits of nCRT has not been established.
Study design: The 2006-2012 National Cancer Data Base was queried for patients with stage II and III rectal adenocarcinoma who underwent nCRT followed by surgical resection. Time to surgery was defined as the difference between last date of radiotherapy and date of surgery. Primary study endpoints included resection margin positivity and pathologic downstaging. Multivariable regression modeling with restricted cubic splines was used to evaluate the adjusted association between time to surgery and our study endpoints, and to establish an optimal time threshold for surgery.
Results: A total of 11,760 patients were included. Median time to surgery was 53 days (interquartile range [IQR] 43 to 63 days). After adjusting for patient demographic, clinical, tumor, and treatment characteristics, our model determined an inflection point at 56 days after end of radiotherapy associated with the highest likelihood of complete resection and pathologic downstaging. With adjustment, the risk of margin positivity was increased in those who underwent surgery after 56 days from end of radiotherapy (odds ratio [OR] 1.40, 95% CI 1.21 to 1.61, p < 0.001). The likelihood of downstaging was increasing up to 56 days after radiotherapy (≥56 days vs <56 days, OR 1.2, 95% CI 1.02 to 1.23, p = 0.01).
Conclusions: This study objectively determined the optimal time for surgery after completion of nCRT for rectal cancer based on completeness of resection and tumor downstaging. Eight weeks appears to be the critical threshold for optimal tumor response.
Copyright © 2016 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
Comment in
- Discussion.[No authors listed][No authors listed]J Am Coll Surg. 2016 Apr;222(4):374-6. doi: 10.1016/j.jamcollsurg.2016.01.043.J Am Coll Surg. 2016.PMID:27016964No abstract available.
Similar articles
- Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.Probst CP, Becerra AZ, Aquina CT, Tejani MA, Wexner SD, Garcia-Aguilar J, Remzi FH, Dietz DW, Monson JR, Fleming FJ; Consortium for Optimizing the Surgical Treatment of Rectal Cancer (OSTRiCh).Probst CP, et al.J Am Coll Surg. 2015 Aug;221(2):430-40. doi: 10.1016/j.jamcollsurg.2015.04.010. Epub 2015 Apr 23.J Am Coll Surg. 2015.PMID:26206642Free PMC article.
- Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?Ranney DN, Mulvihill MS, Yerokun BA, Fitch Z, Sun Z, Yang CF, D'Amico TA, Hartwig MG.Ranney DN, et al.Eur J Cardiothorac Surg. 2017 Sep 1;52(3):543-551. doi: 10.1093/ejcts/ezx132.Eur J Cardiothorac Surg. 2017.PMID:28498967
- Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer.Freischlag K, Sun Z, Adam MA, Kim J, Palta M, Czito BG, Migaly J, Mantyh CR.Freischlag K, et al.JAMA Surg. 2017 Jun 1;152(6):558-564. doi: 10.1001/jamasurg.2017.0010.JAMA Surg. 2017.PMID:28273303Free PMC article.
- [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].Mátrai Z, Lövey J, Hitre E, Orosz Z, Gödény M, Péley G, Sulyok Z, Rényi Vámos F, Farkas E, Köves I.Mátrai Z, et al.Orv Hetil. 2006 Oct 22;147(42):2011-20.Orv Hetil. 2006.PMID:17165600Review.Hungarian.
- Mucinous Rectal Adenocarcinoma Is Associated with a Poor Response to Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.McCawley N, Clancy C, O'Neill BD, Deasy J, McNamara DA, Burke JP.McCawley N, et al.Dis Colon Rectum. 2016 Dec;59(12):1200-1208. doi: 10.1097/DCR.0000000000000635.Dis Colon Rectum. 2016.PMID:27824706Review.
Cited by
- Multimorbidity by Patient and Tumor Factors and Time-to-Surgery Among Colorectal Cancer Patients in Spain: A Population-Based Study.Luque-Fernandez MA, Redondo-Sanchez D, Lee SF, Rodríguez-Barranco M, Carmona-García MC, Marcos-Gragera R, Sánchez MJ.Luque-Fernandez MA, et al.Clin Epidemiol. 2020 Jan 14;12:31-40. doi: 10.2147/CLEP.S229935. eCollection 2020.Clin Epidemiol. 2020.PMID:32021469Free PMC article.
- Robot-assisted laparoscopic resection of clinical T4b tumours of distal sigmoid and rectum: initial results.Crolla RMPH, Tersteeg JJC, van der Schelling GP, Wijsman JH, Schreinemakers JMJ.Crolla RMPH, et al.Surg Endosc. 2018 Nov;32(11):4571-4578. doi: 10.1007/s00464-018-6210-4. Epub 2018 May 16.Surg Endosc. 2018.PMID:29770881
- Significance of ypTNM stage in determining the prognosis and therapy after surgery for locally advanced rectal cancer.Chen Y, Sun J, Dong X, Sun D, Qu Y.Chen Y, et al.World J Surg Oncol. 2023 Jun 7;21(1):174. doi: 10.1186/s12957-023-03059-w.World J Surg Oncol. 2023.PMID:37287039Free PMC article.
- Formation of Polyploid Giant Cancer Cells Involves in the Prognostic Value of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.Fei F, Zhang M, Li B, Zhao L, Wang H, Liu L, Li Y, Ding P, Gu Y, Zhang X, Jiang T, Zhu S, Zhang S.Fei F, et al.J Oncol. 2019 Aug 29;2019:2316436. doi: 10.1155/2019/2316436. eCollection 2019.J Oncol. 2019.PMID:31558902Free PMC article.
- Effect of interval between neoadjuvant chemoradiotherapy and surgery on oncological outcomes in poor responders with locally advanced rectal cancer: a retrospective cohort study.Luo D, Yang Y, Zhang R, Li Q, Li X.Luo D, et al.Int J Surg. 2023 Jul 1;109(7):1993-2000. doi: 10.1097/JS9.0000000000000438.Int J Surg. 2023.PMID:37184445Free PMC article.
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources